Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019
Dispatch

Melioidosis after Hurricanes Irma and Maria, St. Thomas/St. John District, US Virgin Islands, October 2017

Irene Guendel1, Lisa LaPlace Ekpo1, Mary K. Hinkle, Cosme J. Harrison, David D. Blaney, Jay E. Gee, Mindy G. Elrod, Sandra Boyd, Christopher A. Gulvik, Lindy Liu, Alex R. Hoffmaster, Brett R. Ellis, Tai Hunte-Ceasar, and Esther M. EllisComments to Author 
Author affiliations: Virgin Islands Department of Health, St. Thomas, Virgin Islands, USA (I. Guendel, L. LaPlace Ekpo, C.J. Harrison, B.R. Ellis, T. Hunte-Ceasar, E.M. Ellis); Walter Reed Army Institute of Research, Silver Spring, Maryland, USA (M.K. Hinkle); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.D. Blaney, J.E. Gee, M.G. Elrod, S. Boyd, C.A. Gulvik, L. Liu, A.R. Hoffmaster)

Main Article

Table 1

Culture results and antimicrobial drug susceptibility for Burkholderia pseudomallei isolated from 2 case-patients with melioidosis after Hurricanes Irma and Maria, St. Thomas/St. John District, US Virgin Islands, October 2017*

Patient, culture
 Drug
 MicroScan Walk Away System MIC, µg/mL†
 Result
 CDC MIC, µg/mL
 Result
1, first wound culture Amoxicillin/clavulanate NT NA 4/2 S
Ceftazidime >16 R 4 S
Doxycycline NT NA 1 S
Imipenem NT NA 0.5 S
Tetracycline NT NA 4 S
Trimethoprim/sulfamethoxazole <2/38 S <0.5/9.5 S
Meropenem NT NA 1 ‡
1, second wound culture Amoxicillin/clavulanate NT NA 4/2 S
Ceftazidime >16 R 2 S
Doxycycline NT NA 1 S
Imipenem NT NA 0.5 S
Tetracycline NT NA 4 S
Trimethoprim/sulfamethoxazole <2/38 S <0.5/9.5 S
Meropenem NT NA 1 ‡
2, sputum culture Amoxicillin/clavulanate NT NA 4/2 S
Ceftazidime 4 S 4 S
Doxycycline NT NA 1 S
Imipenem NT NA 0.5 S
Tetracycline NT NA 4 S
Trimethoprim/sulfamethoxazole <2/38 S <0.5/9.5 S
Meropenem NT NA 1 ‡

*CDC, Centers for Disease Control and Prevention; NA, not applicable; NT, not tested; R, resistant; S, susceptible.
†Siemens Healthcare Diagnostics, https://www.siemens-healthineers.com.
‡There are no published breakpoints in the Clinical and Laboratory Standards Institute M45 (9).

Main Article

References
  1. Wiersinga  WJ, Currie  BJ, Peacock  SJ. Melioidosis. N Engl J Med. 2012;367:1035–44. DOIPubMedGoogle Scholar
  2. Cheng  AC, Currie  BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18:383–416. DOIPubMedGoogle Scholar
  3. Wuthiekanun  V, Amornchai  P, Saiprom  N, Chantratita  N, Chierakul  W, Koh  GC, et al. Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand. Antimicrob Agents Chemother. 2011;55:5388–91. DOIPubMedGoogle Scholar
  4. Stewart  T, Engelthaler  DM, Blaney  DD, Tuanyok  A, Wangsness  E, Smith  TL, et al. Epidemiology and investigation of melioidosis, Southern Arizona. Emerg Infect Dis. 2011;17:1286–8. DOIPubMedGoogle Scholar
  5. Benoit  TJ, Blaney  DD, Doker  TJ, Gee  JE, Elrod  MG, Rolim  DB, et al. A review of melioidosis cases in the Americas. Am J Trop Med Hyg. 2015;93:1134–9. DOIPubMedGoogle Scholar
  6. Doker  TJ, Sharp  TM, Rivera-Garcia  B, Perez-Padilla  J, Benoit  TJ, Ellis  EM, et al. Contact investigation of melioidosis cases reveals regional endemicity in Puerto Rico. Clin Infect Dis. 2015;60:243–50. DOIPubMedGoogle Scholar
  7. Sanchez-Villamil  JI, Torres  AG. Melioidosis in Mexico, Central America, and the Caribbean. Trop Med Infect Dis. 2018;3:pii:24.
  8. Gee  JE, Gulvik  CA, Elrod  MG, Batra  D, Rowe  LA, Sheth  M, et al. Phylogeography of Burkholderia pseudomallei Isolates, Western Hemisphere. Emerg Infect Dis. 2017;23:1133–8. DOIPubMedGoogle Scholar
  9. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed (M45). Wayne (PA): The Institute; 2016.
  10. Limmathurotsakul  D, Peacock  SJ. Melioidosis: a clinical overview. Br Med Bull. 2011;99:125–39. DOIPubMedGoogle Scholar
  11. Wuthiekanun  V, Peacock  SJ. Management of melioidosis. Expert Rev Anti Infect Ther. 2006;4:445–55. DOIPubMedGoogle Scholar
  12. Cheng  AC, Jacups  SP, Gal  D, Mayo  M, Currie  BJ. Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int J Epidemiol. 2006;35:323–9. DOIPubMedGoogle Scholar
  13. Merritt  AJ, Inglis  TJJ. The role of climate in the epidemiology of melioidosis. Curr Trop Med Rep. 2017;4:185–91. DOIPubMedGoogle Scholar
  14. Hemarajata  P, Baghdadi  JD, Hoffman  R, Humphries  RM. Burkholderia pseudomallei: challenges for the clinical microbiology laboratory. J Clin Microbiol. 2016;54:2866–73. DOIPubMedGoogle Scholar

Main Article

1These authors contributed equally to this article.

Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external